INAB
In8bio·NASDAQ
--
--(--)
--
--(--)
INAB fundamentals
During Q4 2025, In8bio (INAB) reported revenue of --, a YoY change of 0.00%. Net income was -4.94M, a YoY change of 19.77%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 1.69M -- | 2.87M -- | 1.68M -- | 2.31M -- | 2.36M +39.74% | 3.05M +6.12% | 3.39M +101.73% | 5.85M +153.09% | 6.14M +160.05% | 7.18M +135.38% | 7.40M +118.20% | 7.80M +33.32% | 7.53M +22.46% | 7.71M +7.47% | 7.17M -3.11% | 7.60M -2.56% | 8.64M +14.88% | 8.69M +12.62% | 7.11M -0.84% | 6.22M -18.08% | 5.66M -34.53% | 5.20M -40.14% | 3.97M -44.20% | 5.03M -19.14% | 19.86M -- |
Selling, General and Administrative Expenses | 639.00K -- | 1.09M -- | 624.00K -- | 826.00K -- | 1.12M +74.96% | 986.00K -9.54% | 2.04M +227.08% | 3.16M +282.81% | 3.76M +236.67% | 3.67M +272.72% | 3.14M +54.04% | 3.88M +22.58% | 3.47M -7.81% | 3.58M -2.56% | 3.38M +7.60% | 3.08M -20.64% | 3.74M +7.84% | 3.53M -1.34% | 2.73M -19.24% | 2.63M -14.50% | 2.69M -28.17% | 2.71M -23.18% | 1.86M -31.81% | 2.38M -9.32% | 9.65M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | 3.18M -- | -- -- | -- -- | -- -- | 7.31M +129.82% | -- -- | -- -- | -- -- | 14.46M +97.91% | -- -- | -- -- | 3.38M -- | 3.08M -78.73% | 3.74M -- | 3.53M -- | 2.73M -19.24% | 2.63M -14.50% | 2.69M -28.17% | 2.71M -23.18% | 1.86M -31.81% | 2.38M -9.32% | 9.65M -- |
Research and Development Expenses | 1.05M -- | 1.78M -- | 1.06M -- | 1.49M -- | 1.25M +18.35% | 2.06M +15.70% | 1.35M +27.72% | 2.69M +80.94% | 2.38M +91.24% | 3.50M +69.77% | 4.25M +215.19% | 3.92M +45.96% | 4.38M +84.17% | 4.13M +17.98% | 3.79M -11.02% | 4.52M +15.30% | 4.90M +11.81% | 5.16M +24.72% | 3.31M -12.60% | 3.59M -20.52% | 2.97M -39.38% | 2.49M -51.76% | 2.10M -36.42% | 2.65M -26.32% | 10.21M -- |
Other Operating Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -330.00K -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 1.07M -- | 0 -- | -- -- | -- -- | 0 -100.00% | 0 -- | -- -- |
Operating Income | -1.69M -- | -2.87M -- | -1.68M -- | -2.31M -- | -2.36M -39.74% | -3.05M -6.12% | -3.39M -101.73% | -5.85M -153.09% | -6.14M -160.05% | -7.18M -135.38% | -7.40M -118.20% | -7.80M -33.32% | -7.53M -22.46% | -7.71M -7.47% | -7.17M +3.11% | -7.60M +2.56% | -8.64M -14.88% | -8.69M -12.62% | -7.11M +0.84% | -6.22M +18.08% | -5.66M +34.53% | -5.20M +40.14% | -3.97M +44.20% | -5.03M +19.14% | -19.86M -- |
Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | -- -- | 0 -- | 0 -- | 83.00K -- | 60.00K -- | 23.00K -- | 64.00K -- | 110.00K +32.53% | 107.00K +78.33% | 113.00K +391.30% | 91.00K +42.19% | 421.00K -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -83.00K -- | -60.00K -- | -23.00K -- | -64.00K -- | -110.00K -32.53% | -107.00K -78.33% | -113.00K -391.30% | -91.00K -42.19% | -421.00K -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 83.00K -- | 60.00K -- | 23.00K -- | 64.00K -- | 110.00K +32.53% | 107.00K +78.33% | 113.00K +391.30% | 91.00K +42.19% | 421.00K -- |
Pretax Income From Continuing Operations | -1.69M -- | -2.87M -- | -1.68M -- | -2.31M -- | -2.36M -39.74% | -3.05M -6.12% | -3.39M -101.73% | -5.85M -153.09% | -6.14M -160.05% | -7.18M -135.38% | -7.40M -118.20% | -7.80M -33.32% | -7.53M -22.46% | -7.71M -7.47% | -7.17M +3.11% | -7.60M +2.56% | -8.56M -13.78% | -8.63M -11.85% | -7.09M +1.16% | -6.16M +18.93% | -5.55M +35.18% | -5.09M +40.97% | -3.85M +45.61% | -4.94M +19.77% | -19.44M -- |
Income Tax Expense | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -1.69M -- | -2.87M -- | -1.68M -- | -2.31M -- | -2.36M -39.74% | -3.05M -6.12% | -3.39M -101.73% | -5.85M -153.09% | -6.14M -160.05% | -7.18M -135.38% | -7.40M -118.20% | -7.80M -33.32% | -7.53M -22.46% | -7.71M -7.47% | -7.17M +3.11% | -7.60M +2.56% | -8.56M -13.78% | -8.63M -11.85% | -7.09M +1.16% | -6.16M +18.93% | -5.55M +35.18% | -5.09M +40.97% | -3.85M +45.61% | -4.94M +19.77% | -19.44M -- |
Net Income Attributable to Owners of the Company | -1.69M -- | -2.87M -- | -1.68M -- | -2.31M -- | -2.36M -39.74% | -3.05M -6.12% | -3.39M -101.73% | -5.85M -153.09% | -6.14M -160.05% | -7.18M -135.38% | -7.40M -118.20% | -7.80M -33.32% | -7.53M -22.46% | -7.71M -7.47% | -7.17M +3.11% | -7.60M +2.56% | -8.56M -13.78% | -8.63M -11.85% | -7.09M +1.16% | -6.16M +18.93% | -5.55M +35.18% | -5.09M +40.97% | -3.85M +45.61% | -4.94M +19.77% | -19.44M -- |
Preferred Stock Dividends | 260.00K -- | 304.00K -- | 501.00K -- | -1.06M -- | 706.00K +171.54% | 715.00K +135.20% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income Attributable to Common Stockholders | -1.95M -- | -3.18M -- | -2.18M -- | -3.03M -- | -3.07M -57.30% | -3.77M -18.47% | -3.39M -55.41% | -5.85M -93.10% | -6.14M -100.23% | -7.18M -90.68% | -7.40M -118.20% | -7.80M -33.32% | -7.53M -22.46% | -7.71M -7.47% | -7.17M +3.11% | -7.60M +2.56% | -8.56M -13.78% | -8.63M -11.85% | -7.09M +1.16% | -6.16M +18.93% | -5.55M +35.18% | -5.09M +40.97% | -3.85M +45.61% | -4.94M +19.77% | -19.44M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Basic EPS | -0.59 -- | -0.92 -- | -0.6 -- | -- -- | -0.82 -38.98% | -1 -8.70% | -0.25 +58.33% | -0.31 -- | -0.33 +59.76% | -0.38 +62.00% | -0.34 -36.00% | -0.32 -3.23% | -0.3 +9.09% | -0.27 +28.95% | -0.23 +32.35% | -0.18 +43.75% | -0.2 +33.33% | -5.51 -1940.74% | -4.49 -1852.17% | -0.08 +55.56% | -0.07 +65.00% | -1.24 +77.50% | -0.85 +81.07% | -0.51 -537.50% | -2.67 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.23 -- | -- -- | -0.2 -- | -5.51 -- | -4.49 -1852.17% | -- -- | -0.07 +65.00% | -1.24 +77.50% | -0.85 +81.07% | -- -- | -- -- |
Diluted EPS | -0.59 -- | -0.92 -- | -0.6 -- | -- -- | -0.82 -38.98% | -1 -8.70% | -0.25 +58.33% | -- -- | -0.33 +59.76% | -0.38 +62.00% | -0.34 -36.00% | -- -- | -0.3 +9.09% | -0.27 +28.95% | -0.23 +32.35% | -- -- | -0.2 +33.33% | -5.51 -1940.74% | -4.49 -1852.17% | -- -- | -0.07 +65.00% | -1.24 +77.50% | -0.85 +81.07% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.23 -- | -- -- | -0.2 -- | -5.51 -- | -4.49 -1852.17% | -- -- | -0.07 +65.00% | -1.24 +77.50% | -0.85 +81.07% | -- -- | -- -- |
You can ask Aime
What is In8bio's latest dividend and current dividend yield?What guidance did In8bio's management provide for the next earnings period?Did In8bio beat or miss consensus estimates last quarter?What is In8bio's gross profit margin?What is the market's earnings forecast for In8bio next quarter?What does In8bio do and what are its main business segments?What were the key takeaways from In8bio’s earnings call?What factors drove the changes in In8bio's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
